Perspectives From Those Who Regulate Tissue Banks: The Moderator’s Perspective

Stephen W. Bernstein, Esq.
McDermott, Will & Emery
28 State Street
Boston, Massachusetts 02109
617-535-4062
sbernstein@mwe.com

Movement and Regulation of Tissue for Multiple Purposes by Multiple Parties

Big Picture

- Human Biological Materials - defined by Source, Context, Use & Destination (NB: it may be hard to predict the future - you may end up over- or under-regulating yourself)
- Process by which specimens are obtained from Human Subjects
- Tissue Repository Practices and Rules
- Transfer of Specimens to Central Repositories
- Process to Access Repositories

What are we talking about?

- Raw materials obtained from and/or used for treatment, research, product manufacture, and validation of diagnostics including:
  - cadavers
  - vascularized organs
  - blood and blood components
  - tumor and other tissues
  - ovum and sperm/embryos
  - corneas
  - DNA
  - breast milk
  - fetal tissue

Multiplicity of Regulation - Yet No Common Platform

- Requirements for procurement and subsequent rights to use are subject to varying laws and institutional policies depending on the type of biological materials involved, the circumstances of procurement, the parties involved and the ultimate use of the materials
  - There is no overall federal legislation detailing who has what rights to what materials. State or federal statutory provisions may apply in some circumstances. Case law is developing in litigation between various parties in interest.
  - At the value of biological materials and information derived therefrom continues to be developed and be recognized one can expect more disputes.
  - Many disputes involve difficult ethical as well as factual situations resulting in difficult to anticipate outcomes.

Situational Regulation of Tissue Banking

- Federal Common Rule Human Research Protections
  - If tissue banking is done for research by Institution with Assurance: OHRP
- FDA Human Research Protections
  - If tissue banking is done for research purposes by an Institution subject to FDA because institution will make submissions to FDA or research involves products subject to FDA approval
- Federal Privacy Protections under HIPAA
  - If PHI is disclosed by a Covered Entity, e.g., Academic Medical Center
- “Comprehensive FDA System” (Registration, Good Tissue Practices and Donor Suitability Regulations)
  - If tissue banking is done for purposes of human transplantation
- State Law
  - Buying/Selling tissue, privacy and other laws
A few words about HIPAA . . .

- February, 2004 Guidance and Q & A: Research Repositories, Databases and the HIPAA Privacy Rule
- Tissue Samples themselves are not PHI (yet), but use of associated identifying information implicates Privacy Rule
- Creation of Repository itself requires IRB/Privacy Board involvement; Probably a Protocol unto itself
- Harvesting and Depositing Requires a HIPAA Pathway
  - 164.512(h) - Disclosures for cadaveric organ, eye or tissue donation and transplantation — too narrow; Need the other pathways
- Accessing tissue samples requires a “Second” HIPAA Pathway
  - Because, likely that “First HIPAA Pathway” for deposit wasn’t specific enough
- Don’t forget about the Common Rule and IRB’s ongoing involvement

The Regulators

- Julie Kaneshiro, MA  
  Policy Team Leader,  
  Office for Human Research Protections
- Sally Hojvat, Ph.D, MSc.  
  Director, Microbiology Division  
  Food and Drug Administration
- Elizabeth L. Hohmann, M.D.  
  Chair and Director,  
  Human Research Committees  
  Brigham and Women’s Hospital  
  Massachusetts General Hospital